PDF icon Download PDF
Onkologische Welt 2024; 15(07): 410-414
DOI: 10.1055/a-2437-4009
Kongressnachlese

Etablierte Therapien und „New Kids on the Block“

Alexander Kretzschmar
München
› Author Affiliations
› Further Information
Also available ateRef
   Permissions and Reprints
Preview

Die World Conference on Lung Cancer (WCLC 2024) ist der weltweit größte Kongress über Malignome des Brustraumes, vor allem Lungenkarzinomen. Rund 7000 Teilnehmer*innen trafen sich kürzlich in San Diego auf der 50. Jahrestagung der Fachgesellschaft. Vor allem die zahlreichen vorgestellten neuen Studiendaten zur Therapie des nicht-kleinzelligen Lungenkarzinoms (NSCLC) und des fortgeschrittenen (extensive stage) kleinzelligen Lungenkarzinoms (ES-SCLC) zeigen eine gut gefüllte Forschungspipeline in diesen Indikationen. Eine kleine Auswahl.



Publication History

Article published online:
08 November 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Zhou C. et al. Phase 3 study of ivonescimab (AK112) vs. pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: Primary analysis of HARMONi-2. WCLC 2024 Abstract PL02.04
    Search in Google Scholar
  • 2 Yang L. et al. Osimertinib With or Without Savolitinib as 1 L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial. WCLC 2024 Abstract PL04.10
    Search in Google Scholar
  • 3 Cascone T. et al. NeoCOAST-2: Efficacy and safety of neoadjuvant durvalumab (D) + novel anticancer agents + CT and adjuvant D + novel agents in resectable NSCLC. WCLC 2024 Abstract PL02.07
    Search in Google Scholar
  • 4 Kato T. et al. Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study. WCLC 2024 Abstract OA12.03
    Search in Google Scholar
  • 5 Wrangle J. et al. P. IL15 superagonist (N-803, Anktiva) + checkpoint inhibitor (CPI) prolongs OS in 2ndline or greater NSCLC patients failing CPI. WCLC 2024 Abstract OA06.05
    Search in Google Scholar
  • 6 Garassino MC. et al. Sacituzumab govitecan vs docetaxel in patients with mNSCLC non-responsive to last anti-PD-(L)1-containing regimen: EVOKE-01. WCLC 2024 Abstract OA08.06
    Search in Google Scholar
  • 7 Gadgeel S. et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: Longer follow-up of the MARIPOSA study. WCLC 2024 Abstract OA02.03
    Search in Google Scholar
  • 8 Rudin CM. et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of Ideate-lung01. WCLC 2024 Abstract OA04.03
    Search in Google Scholar
  • 9 Dowlati A. et al. Sacituzumab govitecan as second-line treatment in patients with extensive-stage small cell lung cancer. Presented at WCLC 2024. Abstract OA04.04